Plate VI · The field questions
BPC-157 TB-500 questions, answered from the record.
The questions people actually ask about the Wolverine blend, with direct answers cited to the published literature — and the gaps marked as gaps.
Identity and mechanism
These BPC-157 TB-500 answers cover what each peptide is and how it works.
What Is the Wolverine Peptide Blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack" [4]. It is not a single chemical entity and not an approved product; commercial vials carry a combined mass but no clinically validated ratio [4].
What Are BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a human gastric-juice protein — the cytoprotective and angiogenic component [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 — the cytoskeletal, cell-migration component [3][8].
What Is the Difference Between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein, acting as a cytoprotective and angiogenic signal [1]; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4, acting as a cytoskeletal actin-sequestration signal [3]. They are structurally unrelated, with distinct mechanisms [4].
How Does TB-500 Work?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1, sequestering it and regulating the cytoskeletal dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3]. Structural work on a thymosin beta-4-actin complex established the dual-end capping basis of this mechanism [3].
How Does BPC-157 Work Compared to TB-500?
BPC-157 is reported to up-regulate VEGFR2 with downstream Akt-eNOS angiogenic signaling, modulate the nitric-oxide system, and sensitize tendon fibroblasts via growth-hormone-receptor up-regulation [1][2]. TB-500 instead sequesters G-actin to regulate cell migration [3]. The pathways are largely distinct.
Combination, evidence, and efficacy
These answers cover why the two are paired and what the evidence does — and does not — show.
Why Are BPC-157 and TB-500 Combined?
The pairing rationale is that BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 supplies a cytoskeletal actin-sequestration signal driving cell migration [4]. The two are described as complementary but largely non-overlapping; no controlled combination study has defined a synergistic dose, ratio, or endpoint [9].
Is the Combination Synergy Actually Demonstrated?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides given together; a 2025 systematic review of BPC-157 (36 studies, only 1 human) makes no mention of TB-500 or combination use [9]. "Synergy" is a theoretical extrapolation from each peptide's separate mechanism.
Are There Human Trials of the Combination?
No. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies [11], and "TB-500" human data are for full-length thymosin beta-4 — Phase 1 intravenous studies [6][7] — not the heptapeptide.
What Does Tendon and Ligament Research Show?
In rodent models, BPC-157 accelerated healing of a transected Achilles tendon and improved ligament and tendon-to-bone healing [1]; thymosin beta-4 enhanced medial collateral ligament healing [4]. These are animal findings for the individual constituents, not human or combination data.
What Does Muscle-Recovery Research Show?
Animal studies report BPC-157 aiding recovery of crushed muscle and muscle-to-bone reattachment, and thymosin beta-4 acting as a myoblast chemoattractant [4]. Effects are preclinical; no controlled human recovery data exist for the blend.
Do Both Peptides Promote Angiogenesis?
Yes, by distinct routes in animal and cell models: BPC-157 via VEGFR2 up-regulation and the VEGFR2-Akt-eNOS pathway [2], and thymosin beta-4 via endothelial migration [4]. Both have been reported to increase vessel formation and tissue perfusion preclinically.
What Does the Most Recent Research Say?
Recent reviews (2024-2026) consolidate strong preclinical promise for BPC-157 while stressing extremely limited human data; a 2025 systematic review [9] and a 2026 narrative review [10] conclude the evidence is low-tier with scarce human safety data and no controlled combination study.
What Do Recent Reviews Conclude?
Recent peer-reviewed reviews describe BPC-157 as showing promise for musculoskeletal recovery but only from level IV-V evidence with no clinical safety data, treat it as investigational [9][11], and note that unapproved musculoskeletal peptides including BPC-157 and TB-500 operate largely outside regulatory oversight [10].
Pharmacokinetics and handling
These answers report what studies recorded, never a protocol for use.
What Is the Half-Life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported under 30 minutes in a rat and beagle-dog PK study [5]; no validated human half-life exists for either constituent at research doses, and none for the blend. Human full-length thymosin beta-4 showed dose-proportional pharmacokinetics [6][7], but no specific half-life is established for the TB-500 heptapeptide.
How Do You Reconstitute a BPC-157 / TB-500 Blend?
Both constituents are supplied as lyophilized powders for research use and are reconstituted in bacteriostatic or sterile water and refrigerated [4]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed; this describes research handling only, not human-use guidance.
How Often Should BPC-157 and TB-500 Be Administered in Research?
There is no validated dose or frequency for the blend. The underlying rodent studies used intraperitoneal dosing schedules per model [1][4]; community "loading then maintenance" blend protocols have no controlled-trial basis.
How Much BPC-157 and TB-500 Has Been Used in Studies?
No validated weekly dose exists for the blend. Animal-model reference points include BPC-157 around 10 µg/kg and 10 ng/kg in rodents [1], and full-length thymosin beta-4 across a wide range in animal studies [4]; these are not human dosing recommendations.
Can BPC-157 and TB-500 Be Taken Orally Instead of Injected?
BPC-157 is studied as a "stable gastric" peptide, and oral blend products are marketed, but they lack validated pharmacokinetics [5]. Predominant research-community routes are subcutaneous and intramuscular; the underlying efficacy studies for both peptides were largely intraperitoneal [1][4].
Can BPC-157 and TB-500 Be Mixed in One Syringe?
A common research practice is to reconstitute the two peptides separately or in a shared vial, but no controlled study validates a co-formulation, ratio, or combined dose [4]. Identity and purity of unregulated "Wolverine" material are unverified outside formal studies.
Safety and regulatory status
These answers cover the safety signals and the regulatory record.
What Are the Reported Safety Concerns?
Long-term human safety is unknown for both constituents and for the blend. A key concern is that thymosin beta-4 is implicated in tumor metastasis and angiogenesis, so its pro-migratory, pro-angiogenic properties could theoretically support tumor progression [4]; combining two unapproved peptides doubles the uncertainty, and a 2026 review notes potential for serious harm across this class [10].
Does TB-500 Promote Tumor Growth?
Thymosin beta-4 has been implicated in tumor metastasis and angiogenesis in cancer models [4]. This is a theoretical safety signal rather than evidence of cancer causation in humans, but the same pro-angiogenic, pro-migratory properties that aid repair could, in principle, support tumor progression.
Is the Wolverine Blend Legal?
Neither BPC-157 nor TB-500 is an FDA-approved drug, both are currently in FDA's 503A Category 2 (restricting routine compounding access as the record stands), and both are prohibited in sport by WADA [12]. The full picture is on the Wolverine legal status and 503A category page.
Can BPC-157 Be Obtained From a Compounding Pharmacy?
BPC-157 is currently in FDA's 503A Category 2 — identified as potentially presenting significant safety risks, effective with the September 29, 2023 list update — which is not within FDA's enforcement-discretion policy, restricting routine compounding access now [12]. It is also on the scheduled July 2026 PCAC agenda as a candidate under evaluation [14].
What Is the FDA 503A Status of the Wolverine Components?
Both constituents are unapproved research substances, and both are currently in FDA's 503A Category 2 (effective September 29, 2023) [12]. Both are also on the scheduled July 23-24, 2026 PCAC agenda as candidates "being considered for inclusion on the 503A Bulks List" — a discussion under evaluation, not a listing decision [14].